Circle Wealth Management LLC Has $2.10 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Circle Wealth Management LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 7.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,550 shares of the medical research company’s stock after purchasing an additional 235 shares during the quarter. Circle Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $2,097,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 16.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,855 shares of the medical research company’s stock worth $30,628,000 after buying an additional 7,238 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 1,359.7% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 10,612 shares of the medical research company’s stock worth $6,268,000 after buying an additional 9,885 shares in the last quarter. Marietta Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.3% during the 1st quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock worth $7,626,000 after buying an additional 529 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock worth $472,459,000 after buying an additional 4,340 shares in the last quarter. Finally, Kingfisher Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% during the 1st quarter. Kingfisher Capital LLC now owns 8,200 shares of the medical research company’s stock worth $4,843,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 86.50% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, Director Jim P. Manzi sold 814 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $597.24, for a total value of $486,153.36. Following the sale, the director now directly owns 15,807 shares in the company, valued at approximately $9,440,572.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Stephen Williamson sold 12,300 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the sale, the chief financial officer now directly owns 43,944 shares in the company, valued at $26,519,325.12. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 814 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $597.24, for a total value of $486,153.36. Following the sale, the director now owns 15,807 shares in the company, valued at $9,440,572.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,397 shares of company stock worth $33,012,754. Company insiders own 0.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Morgan Stanley increased their target price on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Credit Suisse Group assumed coverage on Thermo Fisher Scientific in a report on Wednesday, August 24th. They issued a “neutral” rating and a $675.00 target price on the stock. Barclays increased their target price on Thermo Fisher Scientific to $685.00 in a report on Tuesday, August 9th. Finally, SVB Leerink increased their target price on Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $662.07.

Thermo Fisher Scientific Trading Up 0.5 %

NYSE TMO opened at $569.40 on Friday. The stock has a market capitalization of $223.09 billion, a price-to-earnings ratio of 30.30, a PEG ratio of 1.77 and a beta of 0.85. Thermo Fisher Scientific Inc. has a one year low of $497.83 and a one year high of $672.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.13. The business’s fifty day moving average is $567.33 and its 200-day moving average is $558.14.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, topping analysts’ consensus estimates of $4.92 by $0.59. The company had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the previous year, the business posted $5.60 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date of this dividend is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.39%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.